治疗无症状高尿血和高血压的慢性病的尿酸降低药物:一项随机试验
Kentaro Kohagura1, Atsushi Satoh2, Masako Kochi3
1Dialysis Unit, University of the Ryukyus Hospital, Nishihara-cho.
Journal of hypertension
|June 19, 2023
概括
费布克索斯塔特和博马龙在 G3 阶段慢性脏病 (CKD) 患者的功能衰退减缓方面表现相似. 这项研究发现,这两种尿酸降低药物之间的估计膜过率 (eGFR) 变化没有显著差异.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 慢性病 (CKD) 的进展是一个重大的健康问题.
- 尿酸降低药物,包括氨酸氧化酶 (XO) 抑制剂和尿酸剂,用于治疗慢性病患者的高尿素血症.
- 不同的尿酸降低疗法对功能下降的比较有效性仍然不清楚.
研究的目的:
- 为了比较febuxostat (一种XO抑制剂) 和benzbromarone (一种尿尿素药物) 在减缓G3期CKD,高血压和高尿素血症患者的功能下降的疗效.
- 评估这些治疗对估计的膜过率 (eGFR) 和其他相关生物标志物的影响.
主要方法:
- 一个开放的,随机的平行组临床试验,涉及95名患有G3期CKD,高血压和高尿血的患者.
- 患者被分配给接受febuxostat或benzbromarone,治疗的标位为达到血清尿酸盐水平低于6.0 mg/dL.
- 主要终点是52周的eGFR变化;次要终点包括尿酸,血压,尿与肌素的比率和XO活性的变化.
主要成果:
- 在52周内,在febuxostat和benzbromarone组之间对eGFR的变化没有发现显著差异.
- 这两种治疗都有效降低了血清尿酸盐水平,但与博马龙相比,费布斯塔特显著降低了XO活性.
- 亚组分析表明,在CKD G3a患者中,febuxostat的EGFR下降可能较慢,但在G3b患者中并非如此. 对于这两种药物,没有发现任何特定的不良反应.
结论:
- 费布克索斯塔特和博马龙在减缓G3阶段慢性病,高血压和高尿血症患者的功能衰退方面表现出相似的疗效.
- 虽然这两种药物都能控制高尿血症,但费布斯塔特独特地抑制了XO活性.
- 进一步的研究可能会探索特定的患者亚组,其中一个药物可能会提供明显的优势.
相关概念视频
01:27Urinary Tract Calculi IV: Nutrition Therapy and Prevention
11
Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
11
01:30Urinary Tract Calculi III: Medical Management
9
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
9
01:28Chronic Kidney Disease III: Interprofessional Care
50
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
50
01:16Antihypertensive Drugs: Action of Diuretics
820
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
820
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
40
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
40
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
19
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
19